{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": [
        "Concomitant use with other anticoagulants (except as specified in protocol for treatment switching)",
        "Concomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor)",
        "Aspirin over 165 mg daily",
        "Dual antiplatelet therapy",
        "Concomitant use of strong inducers of both CYP3A4 and P-gp (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, St. John\u2019s Wort) with apixaban"
    ]
}